Notice - Prescription Drug List (PDL): Mometasone furoate

August 12, 2015
Our file number: 15-109112-943

The purpose of this Notice of Amendment is to notify that Health Canada has revised the listing for Adrenocortical hormones on the Prescription Drug List (PDL) to allow the nonprescription use of Mometasone furoate for the conditions listed below. Only the Human part of the PDL was revised. Health Canada has conducted a scientific review of Mometasone furoate against a set of established and publicly available criteria outlined in section C.01.040.3 of the Food and Drug Regulations. The listing now reads:

Drugs containing the following: Adrenocortical hormones or their salts or derivatives

Including (but not limited to): Hydrocortisone, Hydrocortisone acetate, Hydrocortisone valerate, Hydrocortisone sodium succinate, Clobetasone butyrate, Difluprednate and Mometasone furoate

Qualifier: Mometasone furoate for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg/spray for those 12 years of age and older.

Effective Date: from the date of this Notice

Should you have any questions on this update to the Prescription Drug List, please contact:

Prescription Drug Status Committee
Health Canada
Holland Cross, Tower B, 2nd Floor
1600 Scott Street
Address Locator 3102C3
Ottawa, Ontario
K1A 0K9

Email: drug_prescription_status-statut_d'ordonnance_des_drogues@hc-sc.gc.ca
Telephone: 613-957-1058
Facsimile: 613-941-5035